Drugging the Epigenome: Overcoming Resistance to Targeted and Immunotherapies in Melanoma
This past decade has seen tremendous advances in understanding the molecular pathogenesis of melanoma and the development of novel effective therapies for melanoma. Targeted therapies and immunotherapies that extend survival of patients with advanced disease have been developed; however, the vast ma...
Saved in:
Main Authors: | Ailish Hanly (Author), Frederick Gibson (Author), Sarah Nocco (Author), Samantha Rogers (Author), Muzhou Wu (Author), Rhoda M. Alani (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IGF2BP1, a New Target to Overcome Drug Resistance in Melanoma?
by: Yufeng Xi, et al.
Published: (2022) -
Epigenetics and Epigenomics
Published: (2014) -
Targeting the epigenome in in-stent restenosis: from mechanisms to therapy
by: Xi Yang, et al.
Published: (2021) -
Molecular genomic and epigenomic characteristics related to aspirin and clopidogrel resistance
by: Jei Kim, et al.
Published: (2024) -
Glycan targeting nanoparticle for photodynamic immunotherapy of melanoma
by: Yonghyun Choi, et al.
Published: (2023)